Injection of anti-VEGF-antibody or corticosteroid or any drug into vitreous body

PheWeb

DM_EYE_OPER_VEGF_INJECT_VITR

No definition available.

Endpoint definition

↥

FinnGen phenotype data

321302 individuals

Apply sex-specific rule None

321302

Check conditions None

321302

Filter registries

Operations: NOMESCO codes ^CKD05

4575

Check pre-conditions, main-only, mode, ICD version None

4575

Check minimum number of events None

4575

Include endpoints None

4575

DM_EYE_OPER_VEGF_INJECT_VITR

Extra metadata

First used in FinnGen datafreeze DF2

Similar endpoints

↥

List of similar endpoints to Injection of anti-VEGF-antibody or corticosteroid or any drug into vitreous body based on the number of shared cases.

Broader endpoints:

Narrower endpoints:

None

Show all endpoint correlations

Summary Statistics

↥

Key figures

	All	Female	Male
Number of individuals	4453	2162	2291
Unadjusted prevalence (%)	1.44	1.25	1.70
Mean age at first event (years)	69.26	70.28	68.29

Mortality

Follow-up	Absolute risk	HR [95% CI]	p	N
1998–2019	0.03	2.37 [1.64, 3.44]	5.0e-6	426
15 years	0.01	0.83 [0.56, 1.23]	3.5e-1	147
5 years	0.00	2.40 [1.79, 3.21]	3.7e-9	224
1 year	0.00	2.72 [1.89, 3.91]	5.8e-8	55

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

↥

Index endpoint: DM_EYE_OPER_VEGF_INJECT_VITR – Injection of anti-VEGF-antibody or corticosteroid or any drug into vitreous body
GWS hits:

Survival analyses between endpoints

↥

Plot

before Injection of anti-VEGF-antibody or corticosteroid or any drug into vitreous body
after Injection of anti-VEGF-antibody or corticosteroid or any drug into vitreous body

Loading survival analyses plot

Table

Loading survival analyses table

Drugs most likely to be purchased after Injection of anti-VEGF-antibody or corticosteroid or any drug into vitreous body

↥